

Sofosbuvir/Ledipasvir plus Ribavirin achieves high SVR12 in genotype-3 patients with compensated cirrhosis and similar to Sofosbuvir plus Daclatasvir. A multicentre real life cohort

Mar Riveiro-Barciela^{1,2}, Sonia Alonso³, Inmaculada Fernandez¹⁹, Diego Rincon²⁰, Yolanda Real⁴, Javier Crespo⁵, Francisco Gea⁶, Antonio Oliveira⁷, Jose L. Calleja⁸, Benjamin Polo Lorduy⁹, Jose Antonio Carrion¹⁰, Juan Arenas¹¹, Maria Jose Devesa¹², Carme Baliellas¹³, Angeles Castro¹⁴, Manuel Romero-Gomez¹⁵, Rafael Granados¹⁶, Juan Manuel Pascasio¹⁷, Martin Prieto¹⁸, Javier Salmeron²¹, Ester Badia²², Jose M. Moreno²³, Xavier Fornis²⁴, Juan Turnes²⁵, Jose Luis Montero²⁶, Rafael Esteban^{1,2}, Conrado M. Fernandez-Rodriguez³

¹Liver Unit, Internal Medicine Department, Vall d'Hebron hospital, Barcelona, Spain; ²Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; ³Gastro-enterology, Hospital Universitario Fundación Alcorcón, Madrid, Spain; ⁴Hospital Universitario La Princesa, Madrid, Spain; ⁵Gas-troenterology, Hospital Marqués de Valdecilla, Santander, Spain; ⁶Hospital Universitario Ramón y Cajal, Madrid, Spain; ⁷Hospital Universitario La Paz, Madrid, Spain; ⁸Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain; ⁹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; ¹⁰Hospital del Mar, Barcelona, Spain; ¹¹Hospital Universitario Donostia, Donostia, Spain; ¹²Hospital Universitario Clínico San Carlos, Madrid, Spain; ¹³Hospital Universitari de Bellvitge, Barcelona, Spain; ¹⁴Hospital Universitario de A Coruña, A Coruña, Spain; ¹⁵Hospital Virgen de Valme, Sevilla, Spain; ¹⁶H. U. de Gran Canaria Dr. Negrín, Gran Canaria, Spain; ¹⁷H. U. Virgen del Rocío, Sevilla, Spain; ¹⁸HU La Fe, Valencia, Spain; ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain; ²⁰Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²¹H. U. San Cecilio, Granada, Spain; ²²Hospital Universitario de Burgos, Burgos, Spain; ²³C. H. U. de Albacete, Albacete, Spain; ²⁴Hospital Clínic, Barcelona, Spain; ²⁵Complejo Hospitalario de Pontevedra, Pontevedra, Spain; ²⁶H. Reina Sofía, Córdoba, Spain

Background and aims: Current antiviral therapy for HCV genotype (GT) 3-associated cirrhosis achieves suboptimal sustained virological response (SVR) rates. Daclatasvir (DCV) + Sofosbuvir (SOF) ± ribavirin (RBV) is the only all-oral recommended option due to lower SVR rates of SOF/LDV in patients with cirrhosis. We aimed to evaluate the efficacy and safety of 12 and 24-week SOF+DCV or SOF/LDV ± RBV in a real-life cohort of GT3 patients with cirrhosis.

Patients and methods: Multicenter observational study from two different databases: HepaC-AEEH and Community of Madrid Regional registry. All HCV-cirrhotic patients mono-infected by GT3 and treated with SOF plus a NS5A inhibitor (DCV or LDV) ± RBV between May 2014 and October 2015 were included.

Results: 282 patients were included: 83% male, age 54 years (26-82), 124 (44%) treatment-experienced, 48 (17%) decompensated, 130 (46%) FibroScan >20 kPa and 65 (23%) MELD score>10.195 (69%) received SOF+DCV and 87 (31%) SOF/LDV. Over-all, 88% received RBV. The addition of RBV and extension to 24 weeks were higher in the SOF/LDV group (95% vs. 84%, $p=0.004$; 83% vs. 62%, $p<0.001$). A higher percentage of decompensated patients were treated with DCV (21% vs. 10%, $p=0.029$). 208 patients have reached week 12 of follow-up. Overall SVR12 was 93.8% (195/208), 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 rates are summarized in table. 13 failures were observed (9 relapses, 1 virological failure, 3 deaths). Previous treatment did not impact on SVR. Platelet <75,000/mL was the only factor associated with nonSVR12 (RR: 3.50; 95%CI 1.23-9.94; $p=0.019$). In patients with MELD <10 or albumin >3.5 mg/dL, type of NS5A inhibitor did not impact on SVR12 (93% vs 97%, RR 0.96, 95%CI 0.89-1.04; 93% vs 96%, RR 0.97, 95%CI 0.90-1.05, respectively). Only 16 patients (5.7%) presented serious adverse events (SAE), including 3 deaths (1.1%) and 6 discontinuations

(3.2%). Percentage of SAEs and deaths was higher in decompensated patients (18% vs. 3.1%, $p<0.001$, 4% vs. 0.4%, $p=0.08$). SVR12 of all cohort will be presented at the meeting.

Conclusions: SOF/LDV+RBV achieved high SVR12 rates in GT3 patients with compensated cirrhosis, similar to SOF+DCV, both with low rates of serious adverse events.

		SVR n (%)	95 CI
SOF+DCV+RBV	Child A	82/87 (94,2%)	0,87-0,98
SOF+DCV+RBV	Child B/C	17/18 (94,4%)	0,72-0,99
SOF+DCV	Child A	10/11 (91,0%)	0,58-0,99
SOF+DCV	Child B/C	14/15 (93,3%)	0,68-0,99
SOF/LDV+RBV	Child A	61/64 (95,3%)	0,86-0,99
SOF/LDV+RBV	Child B/C	7/9 (77,7%)	0,39-0,97
SOF/LDV	Child A	4/4 (100%)	0,39-1
SOF/LDV	Child B/C	0/0	NA

Disclosures:

Sonia Alonso - Consulting: Abbvie, Gilead; Speaking and Teaching: Abbvie, Bayer, MSD

Javier Crespo - Advisory Committees or Review Panels: Abbvie, Janssen, BMS; Grant/Research Support: MSD, Gilead

Antonio Oliveira - Consulting: MSD; Speaking and Teaching: Abbvie, Gilead, MSD

Jose L Calleja - Advisory Committees or Review Panels: Gilead, Abbvie ; Speaking and Teaching: Abbvie, Gilead, Janssen, BMS

Juan Arenas - Advisory Committees or Review Panels: Abbvie; Speaking and Teaching: MSD, BMS, Gilead

Rafael Granados - Advisory Committees or Review Panels: Abbvie; Consulting: Janssen; Speaking and Teaching: Abbvie, Janssen, Gilead

Martin Prieto - Advisory Committees or Review Panels: Gilead, Abbvie, Bristol

Xavier Fornas - Consulting: gilead, abbvie, jansen

Juan Turnes - Advisory Committees or Review Panels: Gilead, Abbvie, Janssen, BMS; Speaking and Teaching: MSD, Gilead, Janssen, BMS, Abbvie

Rafael Esteban - Speaking and Teaching: MSD, BMS, Novartis, Gilead, Glaxo, MSD, BMS, Novartis, Gilead, Glaxo, Janssen

The following people have nothing to disclose: Mar Riveiro-Barciela, Inmaculada Fernandez, Diego Rincón, Yolanda Real, Francisco Gea, Benjamin Polo Lorduy, Jose Antonio Carrion, Maria Jose Devesa, Carme Baliellas, Angeles Castro, Manuel Romero-Gomez, Juan Manuel Pascasio, Javier Salmeron, Ester Badia, Jose M. Moreno, Jose Luis Montero, Conrado M. Fernández-Rodríguez